ClinicalTrials.gov
ClinicalTrials.gov Menu

A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM (INSIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01523405
Recruitment Status : Completed
First Posted : February 1, 2012
Last Update Posted : September 8, 2014
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a non-interventional, cross sectional, multicentric study in T2DM patients which will involve a single visit for study related procedures. This study will be conducted in approximately 5,000 patients at around 300 hospitals/primary care clinics across India. Approximately 18-20 patients per site will be enrolled. This study has been designed to evaluate diabetes related quality of life (DQoL), frequency and impact of hypoglycaemia in relation to HbA1c control and to assess disease modifying variables-BMI and BP in T2DM patients on oral / injectable anti-diabetic drugs with/without insulin therapy.

Condition or disease
Type II Diabetes Mellitus

Detailed Description:
A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 4911 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)
Study Start Date : March 2012
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypoglycemia
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
1


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Diabetic Quality of Life using Modified 15 item DQoL (MDQoL) questionnaire [ Time Frame: 2nd February 2012 - 2nd August 2012 ]

Secondary Outcome Measures :
  1. HbA1c and its correlation with frequency of hypoglycemia [ Time Frame: 2nd February 2012 - 2nd August 2012 ]
  2. Frequency and impact of hypoglycemia using HFS-II (worry subscale) [ Time Frame: 2nd February 2012 - 2nd August 2012 ]
  3. Disease modifying variables Body Mass Index (BMI) and Blood Pressure (BP) [ Time Frame: 2nd February 2012 - 2nd August 2012 ]

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Approximately 5,000 adult patients (≥ 18 years) diagnosed with T2DM will be randomly selected from around 300 hospitals/primary care clinics across India to participate in this study.
Criteria

Inclusion Criteria:

  • Patients with diagnosis of T2DM for > 1 year prior to entry in the study willing and able to complete the questionnaire and on pharmacotherapy
  • Patients who are currently treated with a single or combination of injectable/oral antidiabetic drugs with or without insulin therapy
  • Treatment type must be unchanged in the previous 3 months. However, dose modifications are allowed
  • Patients who agree to participate in the study and give their written informed consent

Exclusion Criteria:

  • Patients with type 1 diabetes
  • Patients with diabetic ketoacidosis and/or hyperosmolar hyperglycaemic state
  • Patients with secondary diabetes (including disease of the exocrine pancreas, endocrinopathies)
  • Patients with concurrent treatment involving systemic glucocorticoids. However, inhaled, locally injected and topical use of glucocorticoids is allowed
  • Patients suffering from severe cardiac, hepatic, renal diseases as judged by the investigator
  • Any condition of the patient which may have an impact on objective and outcome of the trial example: patients currently undergoing major/ minor surgical
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01523405


  Show 75 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Abhay Raut, MD Prashanti Clinic,
Principal Investigator: Sashi Kumar, MBBS Dianova Diabetes Centre
Principal Investigator: Subodh Chandra, MD Chandra Medicals Pvt. Ltd
Principal Investigator: Debashish Maji, MD, DM Calcutta Diabetes and endocrine Foundation,
Principal Investigator: Mayur Patel, MD Swasthya (All India Institute of Diabetes and Research)
Principal Investigator: Nallaperumal Sivagnam, MBBS Swamy Diabetes Centre,
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01523405     History of Changes
Other Study ID Numbers: NIS-CIN-XXX-2011/3
First Posted: February 1, 2012    Key Record Dates
Last Update Posted: September 8, 2014
Last Verified: September 2014

Keywords provided by AstraZeneca:
Non Interventional Study, Type II Diabetes Mellitus, Quality of Life

Additional relevant MeSH terms:
Diabetes Mellitus
Hypoglycemia
Diabetes Mellitus, Type 2
 Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases